Eiger BioPharmaceuticals, Inc.
NASDAQ:EIGR
1.725 (USD) • At close April 10, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 15.773 | 13.484 | 12.142 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.024 | 1.837 | 0.745 | 0.645 | 0.486 | 0.054 | 0.041 | 0.023 | 0.011 | 0 | 0 | 0 | 0 |
| Gross Profit
| 15.749 | 11.647 | 11.397 | -0.645 | -0.486 | -0.054 | -0.041 | -0.023 | -0.011 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.998 | 0.864 | 0.939 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 62.331 | 75.282 | 64.436 | 41.59 | 51.791 | 37.091 | 29.519 | 33.014 | 21.959 | 22.676 | 16.927 | 13.314 | 4.193 |
| General & Administrative Expenses
| 0 | 0 | 0 | 20.559 | 17.113 | 13.956 | 12.001 | 13.106 | 12.435 | 10.342 | 3.037 | 2.631 | 1.832 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 25.204 | 29.105 | 23.9 | 20.559 | 17.113 | 13.956 | 12.001 | 13.106 | 12.435 | 10.342 | 3.037 | 2.631 | 1.832 |
| Other Expenses
| 0.087 | -0.963 | 46.487 | -0.012 | -0.015 | -0.012 | 0.186 | -0.277 | 0.005 | -0.835 | 0.025 | 0.147 | 0.152 |
| Operating Expenses
| 87.535 | 104.387 | 88.336 | 62.149 | 68.904 | 51.047 | 41.52 | 46.12 | 34.394 | 33.018 | 19.964 | 15.945 | 6.025 |
| Operating Income
| -71.786 | -92.74 | -76.939 | -62.149 | -68.904 | -51.047 | -41.52 | -46.12 | -42.181 | -33.018 | -19.964 | -15.945 | -6.025 |
| Operating Income Ratio
| -4.551 | -6.878 | -6.337 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -3.171 | -4.013 | 43.086 | -2.902 | -1.348 | -1.344 | -0.928 | -0.967 | -2.232 | -0.835 | -0.127 | 0.074 | -0.965 |
| Income Before Tax
| -74.957 | -96.753 | -33.853 | -65.051 | -70.252 | -52.391 | -42.448 | -47.087 | -44.413 | -33.853 | -20.091 | -15.871 | -6.99 |
| Income Before Tax Ratio
| -4.752 | -7.175 | -2.788 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.006 | 0.023 | 0.064 | 3.582 | 3.391 | 0.985 | 1.669 | 0.39 | 2.307 | -0.153 | -0.012 | 0.101 | 1.276 |
| Net Income
| -74.963 | -96.776 | -33.917 | -68.633 | -73.643 | -52.391 | -42.448 | -47.087 | -44.413 | -33.853 | -19.995 | -15.717 | -6.99 |
| Net Income Ratio
| -4.753 | -7.177 | -2.793 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -50.78 | -69.74 | -0.98 | -2.3 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EPS Diluted
| -50.78 | -69.74 | -0.98 | -2.3 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EBITDA
| -68.741 | -92.621 | -76.939 | -60.812 | -66.36 | -50.062 | -40.924 | -46.397 | -33.82 | -33.018 | -19.803 | -15.699 | -5.793 |
| EBITDA Ratio
| -4.358 | -6.869 | -2.495 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |